A

Alliance for Multispecialty Research, LLC | AMR Knoxville, TN

Research site
(Unclaimed)
Location
1928 Alcoa Hwy, Suite B107, Knoxville, Tennessee, United States of America

Site insights

Top conditions

Top treatments

MK-0616
Orforglipron
MR-100A-01
LY3502970
Ipilimumab
Galcanezumab
MK-2060
Survodutide
DONQ52
Isoamyl Nitrite

Parent organization

This site is a part of Alliance for Multispecialty Research, LLC

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

17 of 21 total trials

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Enrolling
Chronic Kidney Disease
Overweight
Drug: Orforglipron
Drug: Insulin Glargine

The goal of this study is to evaluate the efficacy, safety, and tolerability of MK-0616 in adult participants with hypercholesterolemia. The primary...

Active, not recruiting
Hypercholesterolemia
Familial Hypercholesterolemia
Drug: MK-0616
Drug: Placebo

This is a three-part study of MK-2060 in participants with chronic and/or end-stage kidney disease. The purpose of the study is to evaluate the safet...

Active, not recruiting
End-Stage Renal Disease
End-Stage Kidney Disease
Biological: MK-2060
Drug: Placebo
Locations recently updated

This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult part...

Active, not recruiting
Overweight
Obesity
Drug: Orforglipron
Drug: Placebo

The purpose of this study is to understand the safety and effects of a combined influenza and COVID-19 vaccine. This combined vaccine is compared to...

Active, not recruiting
COVID-19
Influenza
Biological: COVID-19 Vaccine
Biological: Investigational influenza vaccine

The objectives of this first-in-human study is to evaluate the tolerability, safety, and immunogenicity of MVX01, a pneumococcal vaccine candidate, a...

Active, not recruiting
Pneumococcal Vaccine
Biological: MVX01 Placebo
Biological: MVX01

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Lepodisiran Sodium
Drug: Placebo

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Enrolling
Obesity
Drug: Placebo
Drug: survodutide

The purpose of this study is to characterize the safety, tolerability, PK, and efficacy of INCB 99280 in combination with ipilimumab in participants...

Enrolling
Melanoma
Renal Cell Carcinoma (RCC)
Drug: INCB 99280 with Ipilimumab

This study is an open-label, single dose study evaluating the effect of moderate hepatic impairment in the pharmacokinetics of MDMA and its active me...

Begins enrollment in a year or more
Hepatic Impairment
Pharmacokinetics
Drug: Midomafetamine
Locations recently updated

This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of MK-0616, an oral proprotein convertase subtilisin/kexin type 9...

Enrolling
Arteriosclerosis
Hypercholesterolaemia
Drug: Placebo
Drug: MK-0616
Status recently updated

This is an exploratory Phase I, randomized, observer-blind, active-controlled, dose-escalation trial to evaluate four dose levels (DLs) of BNT162b4 g...

Active, not recruiting
Enrolling
COVID-19
SARS-CoV-2 Infection
Biological: BNT162b4 10 µg
Biological: BNT162b4 15 µg

This first-in-human clinical trial, is a dose escalation multi-center trial designed to assess the safety, tolerability, and immunogenicity of the va...

Active, not recruiting
Malaria
Other: Placebo
Biological: BNT165b1

Study of the contraceptive efficacy, cycle control, safety, and tolerability of MR-100A-01 in approxmiately 1200 women for up to 13 cycles

Active, not recruiting
Contraception
Drug: MR-100A-01

This study is to characterize the safety and tolerability of an investigational drug called DONQ52 and consists of a single ascending dose part (Part...

Active, not recruiting
Celiac Disease
Drug: Placebo
Drug: DONQ52

Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a...

Enrolling
Lower Respiratory Tract Illness
Biological: Placebo
Biological: RSVpreF

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Enrolling
Overweight and Obesity
Drug: Retatrutide
Drug: Placebo

Trial sponsors

Lilly logo
BioNTech logo
Merck Sharp & Dohme (MSD) logo
Pfizer logo
Boehringer Ingelheim logo
Chugai Pharmaceutical logo
E
Incyte logo
L
M

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems